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 Abstract - Myelodysplastic syndromes (MDS) are a 
group of clonal hematologic disorders characterized by 
inefficient hematopoiesis, hypercellular bone marrow, 
dysplasia of blood cells and cytopenias. Most patients are 
diagnosed in their late 60s to early 70s. MDS is a risk factor 
for the development of acute myeloid leukemia which can 
occur in 10-15% of patients with MDS. A variety of 
pathophysiologic mechanisms contributes to the genesis and 
persistence of MDS including immunologic, epigenetic, 
cytogenetic and genetic factors. The only potential curative 
option for MDS is hematopoietic cell transplantation which 
is  suitable for only a few patients. Currently approved 
therapeutic options for MDS, including lenalidomide, 
decitabine, and 5-azacytidine, are targeted to improve 
transfusion requirements and quality of life. Moreover, 5-
azacytidine has also been demonstrated to improve survival 
in some patients with higher risk MDS. New ways to predict 
which patients will better gain benefit from currently 
available therapeutic agents are the primary challenges in 
MDS. In the last 10 years, chromosome scanning and high 
throughput technologies (single nucleotide polymorphism 
array genotyping, comparative genomic hybridization, and 
whole genome/ exome sequencing) have tremendously 
increased our knowledge of MDS pathogenesis. Indeed, the 
molecular heterogeneity of MDS supports the idea of 
different therapeutic approaches which will take into 
account the diverse morphologic and clinical presentations of 
MDS patients rather than a restricted therapeutic strategy. 
This review will summarize the molecular abnormalities in 
key relevant components of the biology and pathogenesis of 
MDS and will provide an update on the clinical impact and 
therapeutic response in MDS patients. 
 




I. INTRODUCTION OVERVIEW OF 
MYELODYSPLASTIC SYNDROMES 
 
 Myelodysplastic syndromes (MDS) are a group of 
clonal myeloid disorders which are morphologically 
characterized by bone marrow (BM) hypercellularity, uni- 
or multilineage dysplasia, and peripheral blood 
cytopenias. The incidence rate of MDS in the United 
States for the years 2003-2007 has been estimated at 4.3 
per 100, 000 people which accounts for 15,000 new cases 
every year [1,2]. Statistics on incidence rates might be 
higher due to misdiagnosis of cases with hypocellular BM 
or misinterpretation of the anemia observed in MDS as a 
normal condition in the elderly. It is a disease more 
frequently diagnosed in men with the exception of MDS 
with 5q- syndrome, which is slightly more frequent in 
women. Chromosomal defects are usually clonal and 
recurrent. They are observed in approximately 50% of 
primary and 80% of cases of therapy-related MDS (t-
MDS) [3,4]. The most commonly affected chromosomes 
are 5, 6, 7, 8, 11, 13 and 20 and the most recurrent 
chromosomal lesions are partial deletions (5, 7, 11, 13, 
and 20) and additional copies (6 and 8). Unbalanced 
translocations are also sometimes seen. Single 
chromosomal alterations are usually detected in de novo 
MDS while a complex karyotype, defined as having ≥3 
chromosomal abnormalities is usually observed in MDS 
patients with antecedent exposure to treatments such as 
chemo/ radiotherapy or to toxic chemicals. The latter 
condition is included in the MDS category called 
secondary MDS (sMDS) which includes MDS that 
evolved from a prior hematologic disorder. The impact of 
having multiple chromosomal anomalies has also been 
investigated and correlated with unfavorable outcome in 
patients with sMDS. Cytogenetics has a crucial impact on 
the outcome of patients with MDS and acute myeloid 
leukemia (AML) undergoing hematopoietic stem cell 
transplantation [5]. The accumulation of genetic defects in 
addition to the primary molecular mutation affecting a 
stem cell increases the propensity to develop more 
aggressive diseases like AML. The importance of 
cytogenetic abnormalities in MDS is also due to the fact 
that chromosomal regions often contain genes relevant to 
MDS biology and pathophysiology. Indeed, the presence 
of chromosomal abnormalities like deletions suggests that 
haploinsufficiency and/ or loss of tumor suppressor genes 
(TSGs) are mechanisms important in MDS biology.  
Conventional Sanger sequencing, high resolution 
whole genome scanning technologies (array-based 
comparative genomic hybridization (aCGH) and single 
nucleotide polymorphism arrays (SNP-A) genotyping) and 
high-throughput sequencing technologies (whole genome/ 
exome sequencing) have brought to light molecular 
alterations in genes of numerous pathways including 
methylation, transcriptional factors, signal transduction, 
histone regulators, and the RNA splicing machinery [6]. 
The diversity of these lesions and their combinations may 
reflect the heterogeneity in the morphologic presentations, 
clinical courses, and potentially response to therapeutic 
agents. Ultimately, the finding of genes relevant to MDS 
Molecular Pathogenesis of Myelodysplastic Syndromes 
 
 Valeria Visconte1, Carmine Selleri2,  Jaroslaw P. Maciejewski1,3  Ramon V. Tiu1,3 
1
Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic 
2
Department of Hematology, Oncology, Infectious Disease Branch, University of Salerno, Italy 
3
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, 
Cleveland Clinic, Cleveland OH, USA 
(tiur@ccf.org) 
 
Translational Medicine @ UniSa - ISSN 2239-9747 2014, 8(4): 19-30 
 
20 
Università degli Studi di Salerno 





II. LOW AND HIGH RESOLUTION TECHNOLOGIES 
 
The World Health Organization (WHO) has 
classified MDS into several distinct disease groups 
differentiated from others by BM and peripheral blood 
(PB) morphology (blasts, ring sideroblasts, dysplasia, 
cytopenias) and cytogenetic changes. Different risk 
stratification scoring systems have been created and 
revised for de novo MDS. Metaphase cytogenetics (MC) 
still serves as an important weighted parameter in the risk 
stratification assessment (Figure 1). Classically, MC is the 
gold standard in the determination of cytogenetic 
abnormalities in myeloid cancers. The advantages of MC 
include the simplicity of the method, the detection of 
unbalanced/ balanced chromosomal defects, and the 
feasibility in discriminating single cellular clones. 
However, MC reaches a sensitivity of only 10% and it is 
informative in only 46-59% of patients with MDS due to 
the limitation in achieving results when cells are unable to 
grow or in case of non-informative karyotypes [7.8]. 
Further, even if one-half of MDS patients have a normal 
karyotype by MC, this does not necessarily exclude the 
presence of latent genetic defects not clinically dominant 
which escape detection due to the low resolution of MC. 
A combination of chromosome painting and multi-color 
fluorescence called spectral karyotyping (SKY) has 
complemented the photographic images of condensed 
chromosomes by G-banding and fluorescence in situ 
hybridization (FISH) for specific chromosome (5, 7, and 
20) and improved the detection of chromosomal 
rearrangements and minimal monosomies leading to a 
better picture of the karyotype [9].  
Advances in high resolution genome scanning 
technologies like aCGH and SNP-A have improved the 
detection rate of genomic lesions in MDS and other 
related disorders and have clarified many aspects of MDS 
biology [10]. aCGH is a technology that identifies 
differences in copy number between DNA of patients and
Figure 1. Schema of the diagnostic tests, classification systems, and prognostic/ scoring systems in Myelodysplastic syndromes. Microscopy, 
immunohistochemistry, G-banding, and sometimes flow cytometry are all useful diagnostic tests in Myelodysplastic syndromes (MDS). Prognostic 
markers include: bone marrow and peripheral blood morphology, numbers of blasts, morphologic features (ring sideroblasts), dysplasia, cytopenias and 
cytogenetic changes. Classification systems include (FAB, 2002 and 2008 WHO). Risk stratification scoring systems have been created for de novo 
MDS with and without account for cytogenetic findings. 
Abbreviations. BM, bone marrow; LDH, lactate dehydrogenase; ALIP, abnormal localization of immature precursors; MC, metaphase cytogenetics; 
FAB, French American British Classification; IPSS, International prognostic scoring system; WPSS, WHO classification-based Prognostic Scoring 
System; IPSS-R: International prognostic scoring system-Revised. 
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healthy subjects on the basis of fluorescent hybridization 
signals. SNP-A has combined two techniques commonly 
used in the DNA microarray technologies, DNA 
hybridization and fluorescence. The use of SNP-A has 
overcome a limitation of the aCGH technology and 
provides the ability to detect a cryptic cytogenetic defect 
called acquired somatic uniparental disomy (AS-UPD) 
which is recurrent in 20% of patients with MDS. Several 
studies have reported the clinical importance of both 
aCGH and SNP-A on the survival settings of MDS [11-
14]. However, efforts have been made towards the 
combination of all these approaches with MC and several  
multicenter studies have highlighted the worse survival 
outcomes of patients with MDS and other disorders 
carrying defects detected by MC/ SNP-A in addition to 
several other studies where the number of defects by SNP-
A predict worse outcomes [15-18].  
More recently, high-throughput sequencing, such as 
whole genome/ exome and deep sequencing, has been 
instrumental in discovering germ-line and somatic 
variants in a number of solid tumors and blood cancers 
including MDS. These technologies are able to generate a 
comprehensive sequence database of an individual (whole 
genome), a targeted genome re-sequencing which allows 
for the generation of specific sequences (whole exome) or 
a sequence of the entire genome with higher ‘’depth’’ 
indicating that the process of the sequencing is performed 
more than one time for any one region of the genome 
(deep sequencing). This latest approach has markedly 





III. BIOLOGICAL AND CLINICAL IMPACT OF 
MOLECULAR MARKERS IN MDS 
 
More than a decade ago, cytogenetic defects were 
the foremost determinant of MDS biology. The 
advancement in high resolution genomic technologies 
helped in the identification of regions of the genome 
highly suspected to contain molecular mutations. This was 
the case for the original discoveries of TET2, EZH2, CBL, 
IDH1/ IDH2, ASXL1, DNMT3A, UTX, TP53, SF3B1, 
U2AF1, and SETBP1 (Table 1).  
We will discuss the role of several of these genes 
and pathways for which the biological and clinical impact 





IV. COMMONLY AFFECTED PATHWAYS: 
METHYLATION PATHWAY: TET2, DNMT3A, 
IDH1/2 
 
Aberrant DNA methylation has been observed in 
MDS. Methylation of promoters at CpG loci is one of the 
mechanisms that can regulate and silence TSGs. The 
identification of distinct methylation patterns, 
hypermethylation of key genes important in 
differentiation, and the success of using DNA-
methyltransferase inhibitors (5-aza-2’-deoxycytidine and 
5-azacytidine) in some MDS patients provides the 
rationale supporting the key role of methylation as a cru 
cial regulatory mechanism in MDS. Indeed, several 
studies have demonstrated that the increase in aberrant 
DNA methylation and chromosomal anomalies is directly 
proportional to the malignant transition of MDS to AML 
[19,20].  
 
TABLE 1. FREQUENCY OF MOLECULAR MUTATIONS IN 
MYELOID MALIGNANCIES 
 









TET2* 12 – 14 37 – 46 9 – 43 
IDH1/2* 1 – 5 9 5 – 10 
DNMT3A* 8 12 25 
ASXL1* 21 17 – 46 17 
EZH2 2 4 – 12 1 
CBL 1 - 2 5 9 
SF3B1* 4§  7#  5 – 6 
U2AF1* 6 – 12 8 – 17 1 – 10 
SRSF2* 6 – 12 28 – 47 1 – 7 
TP53* 8 7 56 – 78 
NRAS/KRAS 4/1 7/4 9 – 40/ 5 - 17 
RUNX1* 9 13 13 
SETBP1* 4.1 9.4 0.9-9.1† 
*Indicates the genes discussed in the text. §68% in refractory anemia 
with ring sideroblasts. # 81% on refractory anemia with ring 
sideroblasts associated with thrombocytosis. †frequency for de novo 
and secondary AML, respectively.  
Abbreviations. MDS, Myelodysplastic syndromes; MDS/ MPN, 
Myelodysplastic syndromes/ Myeloproliferative neoplasms; AML, 
Acute myeloid leukemia. 
 
Genes that act as regulators of the DNA methylation 
have been found to be frequently mutated in MDS. SNP-A 
identified a region of loss of heterozygosity on 
chromosome 4q24 which contains a gene called TET2 
which is frequently mutated in MDS. TET2 was mutated 
in 20-25% of MDS patients [21,22]. TET2 is a 
dioxygenase that catalyzes the conversion of the modified 
base 5-methylcytosine (5-MC) to 5-
hydroxymethylcytosine (5-hMC) by oxidizing 5-MC. The 
conversion of 5-MC to 5hMC represents the first step in 
cytosine demethylation. Indeed, methylation at the C5 
position of cytosine appears to be an epigenetic 
modification which plays an important role in 
transcriptional regulation. TET2 mutations are restricted to 
the C- terminus of the protein, resulting in loss of function 
which correlates with a decrease of 5-hMC levels and an 
increase of 5-MC leading to DNA hypermethylation and 
gene silencing [23,24]. Even though TET2 mutations are 
correlated with low 5-hMC levels in myeloid disorders, a 
fraction of patients with wild-type TET2 also have low 5-
hMC levels. A recent report correlated a low level of 5-
hMC to the over-expression of the ancestral CXXC 
domain of TET2 which encodes for a specific gene called 
IDAX [25]. In addition, several reports have described that 
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low 5-hmC levels are associated with DNA 
hypomethylation in patients with myeloid malignancies 
while others have described DNA hypermethylation in 
AML [23]. A mouse model of TET2 loss of function 
shows increased proliferation of myeloid cells without 
manifesting any dysplastic changes resembling MDS [26]. 
The clinical impact of TET2 mutations has been widely 
studied by many groups and somehow is still under 
debate. (Table 2) TET2 mutations do not seem to predict 
an increased risk for transformation to AML. Most studies 
looking at the prognostic value of TET2 in MDS did not 
show a difference in survival outcomes between mutant 
and wild type cases. The efficacy and effectiveness of 
hypomethylating therapy in specific subsets of MDS 
patients and the presence of molecular mutations in genes 
relevant to methylation also justifies the efforts in 
genotyping large cohorts of patients with MDS receiving 
hypomethylating drugs for these specific molecular 
changes. Itzykson and colleagues showed that high-risk 
MDS patients carrying TET2 mutations have better 
response rate to 5-azacytidine without any improvement in 
OS [27]. We demonstrated in a cohort of 92 MDS patients 
that the presence of TET2 and DNMT3A mutations confers 
better response to both azacitidine and decitabine [28].  
Whole genome sequencing was instrumental in the 
identification of a somatic mutation in a DNA 
methyltransferase gene called DNMT3A located on 
chromosome 2 p23.3. DNMT3A catalyzes the addition of a 
methyl group to the cytosine of the CpG dinucleotides. 
The amino terminus of the human DNMT3A gene contains 
various motifs that recruit transcriptional repressors. The 
role of DNTM3A is extremely important since this enzyme 
acts as a check-point of DNA replication by keeping de 
novo methylation mechanisms partially methylated. The 
methylation of the CpG islands induces repression of 
downstream genes. The first genetic alteration identified 
in DNMT3A was a frameshift mutation found in a patient 
with de novo AML [29]. DNMT3A has been found to be 
mutated in 8% of MDS cases [30,31]. The interplay 
between TET2 and DNMT3A has captured the attention of 
many groups, especially for their role in altering the 
cytosine methylation and for the fact that current 
treatments for MDS heavily rely on hypomethylating 
therapy. In vitro murine embryonic stem cells deficient for 
dnmt3a have a competitive advantage compared to cells 
expressing normal DNMT3A, indicating that DNMT3A 
mutations might be clonally dominant [32]. The role of 
DNMT3A in somatic cells is still unknown. Data from 
mouse models has also suggested a role for DNMT3A in 
epigenetic silencing. Hematopoietic stem cells deficient 
for DNMT3A show differential methylation and up-
regulation of multipotency genes. The clinical impact of 
DNMT3A has been correlated with worse OS [33]. 
Moreover, MDS is usually associated with a 
hypermethylation and DNMT-inhibitors are associated 
with increased survival in MDS. 
In 2008, parallel massive sequencing identified 
mutations in the isocitrate dehydrogenase 1 (IDH1) gene 
in gliomas. IDH1 mutations alter the catalytic activity of 
the enzyme producing a toxic oncometabolite called R-2-
hydroxyglutarade which affecting the redox state of the 
cells, blocking the production of NAPDH. The modality 
of how IDH1 promotes the transformation of the normal 
cells is still unclear. Several studies have postulated that 
mutations (either by loss of the normal allele or as a result 
of a dominant-negative effect) might alter the 
mitochondrial function and lead the cells to use glycolysis. 
On the other hand, mutations lead to a hypermethylation 
phenotype with a change in the oxidative metabolism. 
Mutations in two isoforms of this metabolic enzyme 
(IDH1 and IDH2) have been found in many solid and 
blood cancers, including in MDS at a low frequency. This 
finding suggests that malignancies can be caused by 
dysfunction in cellular metabolism. A small proportion of 
late stage MDS cases (5-10%) have IDH1/2 mutations. In 
addition, a slightly higher frequency of mutations in this 
gene is found in sAML patients that evolved from a prior 
MDS (10-20%). The clinical impact of these mutations is 
still controversial and varies in different cancers [34]. The 
higher frequency in patients with higher risk MDS 
suggests a predisposition to develop AML. (Table 2) It 
has recently reported that serum measurement of R-2-
hydroxyglutarade can predict clinical outcome in IDH1/2 
mutant patients [35]. Several studies have indicated an 
increased risk for relapse in AML patients carrying 
IDH1/2 mutations while others have not found any 
statistical correlation. IDH1/2 proteins are interconnected 
with TET2 since TET2 seem to be a target of R-2-
hydroxyglutarate [36]. In addition, TET2 and IDH1/2 




V. HISTONE MODIFICATION: ASXL1, RUNX1 
 
ASXL1 (Additional Sex Combs Like 1) is a gene 
located in chromosome 20q11.21. This mutation appears 
to be independent of the deletion of 20q found in patients 
with MDS, as ASXL1 mutations were found in 28% of 
patients carrying isolated del(20q). ASXL1 is a member of 
the Polycomb family which includes genes implicated in 
chromatin remodeling and gene repression. Indeed, 
several structural similarities have been identified in genes 
of the Drosophilidae where ASXL1 interacts with 
chromosomal elements. The function of the 
ASXL1protein is required for the activation and 
repression of homeotic loci. The protein is believed to 
disrupt chromatin in localized areas of certain genes while 
repressing the transcription of other genes. Indeed, 
mutations lead to the disruption of activating domains 
(PDH, RARalpha, and SRC1). Monoallelic mutations in 
ASXL1 have been found in 16% of high-risk MDS patients 
and in ~30% of patients with AML and a prior MDS 
diagnosis. ASXL1 mutations have been associated with a 
worse OS in MDS [37]. (Table 2)  Mutational analysis has 
also revealed the co-occurrence of ASXL mutations with 
TET2, IDH1/2, and EZH2 mutations, indicating that the 
epigenetic mechanisms in total are highly dominant in 
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MDS pathophysiology [38]. The effect of ASXL1 
mutations is still unclear with some studies pointing 
towards a gain of function and dominant negative effect 
rather than loss of function.  
RUNX1 (Runt related transcription factor), also 
known as AML1, maps to chromosome 21q22 and belongs 
to a family of DNA core binding factors. RUNX1 
regulates the transcription of genes important in 
hematopoietic stem cell formation during embryogenesis. 
Indeed, runx1 knock-out mice die few days after birth 
without achieving complete hematopoiesis.  RUNX1 
translocations produce chimeric proteins, and RUNX1 is 
usually highly mutated in AML (M0, M2, and M1 types), 
while RUNX1 mutations are found in 20% of MDS cases, 
mainly t-MDS and radiation exposure [39].  RUNX1 
mutations occur  near DNA-binding domains altering the
 
TABLE II. EFFECTS OF MOLECULAR MUTATIONS ON OVERALL SURVIVAL AND AML TRANSFORMATION IN 
MYELODYSPLASTIC SYNDROMES AND OTHER MYELOID MALIGNANCIES  
 
Gene Studies Disease Group Overall Survival AML Transformation 
TET2 
Tefferi A et al.  
Leukemia. 
2009;23(7):1343-5.  
CMML (N=15), MDS (N=7), MDS/MPN 
(N=3), Others (N=16)  
- - 
Jankowska A et al.  
Blood. 2009  
18;113(25):6403-10 
MDS (N=14), MDS/MPN with CMML 
(N=30),  Others (N=24) 
no difference - 
Langemeijer SM et al. 
Nat Genet. 
2009;41(7):838-42 
MDS (N=102) no difference no difference 
Kao HW et al.  
52nd ASH Meeting 
Abstract 4019 
MDS (N=161) no difference increased risk 
Jankowska A et al. 
Blood. 2011 
6;118(14):3932-41 
CMML (N=52), CMML to AML (N=20) no difference - 
Bejar R et al.  




no difference - 
Itzykson R et al.  
Leukemia. 
2011;25(7):1147-52 
MDS and AML with 20-30% blast (N=86); 
Tx with 5-aza 
no difference - 
DNMT3A 
 
Walter MJ et al. 
Leukemia. 
2011;25(7):1153-8 
 MDS (N=150) worse 
 
      more rapid progression 
Jankowska A et al.  
Blood. 2011 
6;118(14):3932-41 
CMML (N=52), CMML to AML (N=20) 
 
 
no difference - 
Lin J et al. 
 PloSOne. 
2011;6(10):e26906. 
Epub 2011 Oct 31. 
AML (N=182), MDS (N=51) 
 




Jankowska A et al.  
Blood. 2011 
6;118(14):3932-41 





Bejar R et al.  
N Engl J Med. 2011. 
30;364(26):2496-506 











Gelsi-Boyer V et al.  





Kulasekararaj A et al.  
52nd ASH Meeting 
Abstract 125 
MDS (N=45); AML from MDS (N=9), t-
AML/MDS (N=7), CMML (N=2) 
better if analyzed with 
EZH2 - 
Jankowska A et al.  
Blood. 2011 
6;118(14):3932-41 
CMML (N=52), CMML to AML (N=20) 
 
no difference - 
Thol F et al.  
J Clin Oncol. 2011 
20;29(18):2499-506 
MDS (N=193) 
worse decreased  time to AML 
progression 
 
Bejar R et al.  





Abbreviations. MDS, Myelodysplastic syndromes; MDS/ MPN, Myelodysplastic syndromes/ Myeloproliferative neoplasms; AML, Acute myeloid 
leukemia; CMML, chronic myelomonocytic leukemia; RARS, refractory anemia with ring sideroblasts; RARS-T, refractory anemia with ring 
sideroblasts associated with thrombocytosis; LFS, leukemia free survival; - Indicates not available leukemia; Tx, treatment. 
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TABLE II. EFFECTS OF MOLECULAR MUTATIONS ON OVERALL SURVIVAL AND AML TRANSFORMATION IN 
MYELODYSPLASTIC SYNDROMES AND OTHER MYELOID MALIGNANCIES (CONTINUED) 
 
 
DNA core-binding capacity and appear to be independent 
prognostic factors of worse OS. The mutations induce loss 
of trans-activation. An elegant study conducted in mice 
reported that mice transplanted with human cells carrying 
a mutant RUNX1 allele develop dysplasia in the erythroid 
lineage and MDS features. 
 
 
VI. RNA SPLICING MACHINERY: SF3B1, U2AF1, 
SRSF2 
 
RNA splicing is an evolutionary mechanism 
important in maintaining genomic variability. Splicing 
mutations lead to hereditary diseases, such as X-linked 
disorders of copper metabolism and retinitis pigmentosa 
[40]. Somatic mutations in components of the spliceosome 
machinery were discovered by several groups using whole 
















Visconte V et al. 
Leukemia. 2012 
Mar26(3) :542-5 Epub 
2011 Sep 2  
 
MDS 
MDS/ MPN (N=56) 
           no difference 
 
                    - 
Papaemmanuil E et al.  
NEJM. 2011 Oct 
13;365(15):1384-95. 







Malcovati L et al. 
Blood.  2011 Dec 
8;118(24):6239-46 









clinical data available from  253 patients 
no difference no difference 
Patnaik MM et al.  
Blood  2012 Jan 
12;119(2):569-72   
and Am J Hematol. 
2013 Mar;88(3):201-6 
MDS-RS (N=107) 
univariate analysis better 




Visconte V et al. Blood  
2012 Oct 
18;120(16):3173-86 
MDS and MDS/MPN (N=456) 
better for MDS and 
MDS/MPN and within the 


























Graubert et al. Nat 
Genet. 2012;44: 53-57. 











Yoshida et al. Nature 
2011;478: 64-69 
MDS, MDS/MPN, AML (N=582) 
- 
                          - 
Patnaik MM et al.  Am 




no difference no difference in LFS 


















Makishima et al  Nat 
Genet. 2013 Jul 7. In 
press 
MDS, MDS/ MPN, MPN, AML (N=727) worse 
association with myeloid 
transformation 
Thol F et al.  
Leukemia. 2013 May 7. 
In press 
MDS and AML (N=944) 
no difference 
- 
Abbreviations. MDS, Myelodysplastic syndromes; MDS/ MPN, Myelodysplastic syndromes/ Myeloproliferative neoplasms; AML, Acute myeloid 
leukemia; CMML, chronic myelomonocytic leukemia; RARS, refractory anemia with ring sideroblasts; RARS-T, refractory anemia with ring 
sideroblasts associated with thrombocytosis; LFS, leukemia free survival; - Indicates not available leukemia; Tx, treatment. 
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genome/ exome sequencing in MDS with ring sideroblasts 
(RS) and MDS/myeloproliferative overlap syndromes 
(MDS/ MPN) and later in lymphoid malignancies like 
chronic lymphocytic leukemia (CLL). SF3B1 mutations 
range in frequency, occurring in 68-75% of cases of 
refractory anemia with ring sideroblasts (RARS) and 81% 
in RARS associated with thrombocytosis (RARS-T) [41-
43] while being rare in other diseases [44]. SF3B1 has 
been linked to the pathogenesis of RARS and RARS-T. 
We associated SF3B1 mutations to the presence of RS 
[45,46]. In terms of clinical significance, SF3B1 mutations 
have been associated with better OS (P=.01), leukemia-
free survival (P=.05), event free survival (P=.008) and 
with a lower risk of progression to AML [42]. Better OS 
was noted in RARS/ RARS-T carrying SF3B1 mutations 
[45] (Table 2). No difference in OS and AML 
transformation was found in a cohort of 317 patients with 
MDS. Patnaik et al. determined that the prognostic value 
of SF3B1 mutations was completely accounted for the 
WHO morphologic grouping [47].   
Pharmacologic inhibitors of the spliceosome 
machinery are currently available [48,49]. We described 
functional data on Meayamycin, which specifically targets 
the splicing factor 3b (SF3b) complex [50]. Other 
pharmacologic compounds including spliceostatin, 
FR901464, E7107, pladienolide and Sudemycins are 
currently being investigated. Interestingly, the clinical 
significance of SF3B1 in MDS is different from that 
observed in CLL. The other disease where SF3B1 is 
highly mutated is CLL (15%) [51]. It has been reported 
that SF3B1 mutations predict worse outcome in CLL 
patients, and they are commonly associated with deletion 
of long arm of the chromosome 11, an abnormality 
present in 5-10% of CLL patients. These findings suggest 
that different targets might be involved and also that the 
clonal nature of the two diseases is regulated by different 
drivers. Our laboratory is actively working in 
investigating the molecular mechanisms responsible for 
the good outcomes of patients carrying SF3B1 mutations 
focusing attention on DNA damage differences, iron 
accumulation, mitochondrial targets, and in-vitro response 
to hypomethylating agents. Our preliminary data suggests 
that the presence of SF3B1 mutations confer better 
response rate to erythropoiesis stimulating agents and 
hypomethylating agents [52].  
Mammalian U2 small nuclear ribonucleoprotein 
auxiliary factor (U2AF) is a heterodimer composed of a 
65-kDa subunit (U2AF
65





 contacts the pyrimidine tract while U2AF
35
 
interacts with the AG splice acceptor dinucleotide of the 
target intron at the 3′ splice site. U2AF
35 
is also known as 
U2AF1. Recurrent somatic mutations (S34 and Q157) in 
U2AF1 were found in 8.7% of patients with primary MDS 
and were associated with progression to sAML [53,54]. 
U2AF1 mutations result in a gain of function. Indeed, a 
significant increase in exon skipping was observed when 
the mutant p.Ser34Phe cDNA was transiently expressed in 
vitro [53]. Pattern of splicing for U2AF1 has recently been 
elucidated [55].  
SRSF2 encodes a member of the serine/arginine 
(SR)-rich family of pre-mRNA splicing factors with an 
RNA recognition motif (RRM) and a RS domain. SRSF2 
is believed to be a key element in the acetylation/ 
phosphorylation network and an important regulator of the 
DNA stability. The first report describing SRSF2 
mutations in CMML found mutational frequencies 
ranging between 28.4-47% [56]. The most common 
alteration occurs at amino acid position Prolin95 between 
the RRM motif and the RS domain. SRSF2 has been 
indicated as a new diagnostic target in CMML. The 
presence of SRSF2 mutations correlate with higher age, 
anemia, and normal karyotyping and do not seem to 
impact survival. Other studies associated SRSF2 mutations 
with poor outcomes (Table 2). The impact of baseline 
spliceosomal mutations were investigated in a cohort of 
patients that underwent allogeneic hematopoietic cell 
transplantation, finding that SRSF2 mutants had similar 
outcomes to wild type patients, suggesting that transplant 




VII. INFREQUENT MOLECULAR MUTATIONS 
 
We have discussed the genes for which the 
clinical impact has been intensively studied and correlated 
with the patient phenotypes. Several of the above genes 
are relevant because they can serve as therapeutic targets 
in MDS, like hypomethylating agents and histone 
deacetylase.  On the other hand, there are numerous other 
genes with lower mutational frequencies reported in MDS 
and other related malignancies in the same biological 
pathways discussed above. Mutations in other genes 
regulating histone function and members of the polycomb 
group are less frequent in MDS. EZH2 acts as histone 
methyltransferase that normally works in maintaining the 
repressed status of TSGs and has been found mutated in 2-
6% of patients with MDS [58]. UTX, a demethylase gene 
located in the X chromosome, has been actively 
interrogated for mutations but they have only been found 
in MDS/ MPN patients at a frequency of 6%.  Mutations 
in c-CBL, CBL-b, and CBL-c are extremely rare in MDS 
(1%), while present in a much higher frequency in patients 
with MDS/ MPN (8.1%) [59]. Infrequent mutations in 
other spliceosomal genes, such as U2AF65, ZRSR2, SF1, 
SRSF1, SF3A1, PRF40B, PRPF8, and LUC7L2, were also 
detected [54]. Mutations in N/KRAS,encoding proteins 
homologous to RAS, were reported at frequencies of 2-
6%. Several other genes have been found but are even less 
commonly dysregulated and/ or mutated in MDS like 
IER3, a sentinel of cellular stress, FLT3, a class III 
receptor tyrosine kinase which determines proliferative 
advantage if mutated in AML, and CDC25c, a gene in the 
cell division pathway that interacts with MAP kinase 
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VII. BRIEF DESCRIPTION OF GENES  
ASSOCIATED WITH SPECIFIC CHROMOSOMAL 
ABNORMALITIES: TP53 AND RPS14 
 
Gene mutations can be associated with specific 
classes of MDS patients carrying distinct chromosomal 
anomalies. Mutations in TP53, a TSG, have been 
correlated with anomalies of chromosome 5 (isolated 
del5q, -5/5q-), 17p-, and complex karyotypes, suggesting 
different biological and driving mechanisms. Mutations 
were detected early in the MDS presentation, suggesting a 
primary event in the manifestation of the disease. 
Associations of TP53 mutations and t-MDS have been 
reported. Moreover, mutations have also been correlated 
with response to therapy (5-azacytidine) and seemed to 
disappear upon response [60].  
The discovery of the haploinsufficiency of 
RPS14 and its somatic deletion in patients with 5q- 
syndrome associated MDS to other ribosomopathies and 
correlated this ribosomal protein to the pathogenesis of 
5q- patients. In addition, RPS14 seems to be a major 
player in the anemia of patients with 5q- and a marker of 




IX. NEWLY DISCOVERED MOLECULAR 
MUTATIONS 
 
Whole exome sequencing aided in the discovery of 
mutations in SETBP1 with a higher frequency in atypical 
CML (aCML). Germline alterations in SETBP1 are 
characteristic of the Schinzel-Giedion midface retraction 
syndrome. Heterozygous variants, commonly found in a 
germline configuration, are found to be somatic in aCML 
[62]. Direct sequencing of SETBP1 in different subsets of 
MDS, MDS/ MPN, and other diseases found a lower 
frequency in MDS (2.2%) [63]. SETBP1 mutations have 
been correlated with leukemogenesis [64] and found to be 
associated with the presence of other two genes which 
correlate with a negative prognosis (ASXL1 and EZH2) 
and with two deleterious chromosomal abnormalities 




X.  CONCLUSION 
 
High-resolution genomic technologies have 
discovered a myriad of somatic alterations in different 
genes with a variety of functions in MDS and other 
hematologic malignancies. Even in the era of genomic 
technologies, MC still represents the gold standard in the 
identification of chromosomal abnormalities in MDS and 
still holds a fundamental role in the prognostic scoring 
systems. Molecular mutations represent a new parameter 
to take into account in the risk stratifications models. 
Whole genome/ exome sequencing represents a platform 
of discovery for new markers of MDS, but the role and the 
mechanisms explaining the heterogeneity of the clinical/ 
morphologic manifestations of MDS is still unknown. On 
the other hand, even with the advent of all these 
sophisticated technologies conventional Sanger 
sequencing still represents the most reliable and cost 
affordable technique. Pitfalls including artefacts/ false 
negatives are also commonly faced using the next 
generation technologies as mentioned above. Lower-
frequency molecular mutations are also important in 
MDS, but harder to study in terms of prognostic and 
predictive significance. Nonetheless, they may provide 
important insight in disease biology unique to the specific 
individual carrying the rare mutation. Recurrence of 
somatic alterations is a pre-requisite to define a specific 
gene as a possible candidate in the pathogenesis of a 
disease subtype. We have interrogated hundreds of 
possible candidates selected after performing whole 
exome sequencing in MDS and other related disorders, 
finding sporadic somatic alterations with no detectable 
frequency in large cohort of same disease type. Germ-line 
sources (lymphocytes and/ or buccal swabs when 
possible), scoring of the genetic variants based on an 
acceptable coverage, stringent bioinformatics algorithms, 
searching in public database for SNPs exclusion, absence 
of variants in healthy individuals, and further confirmation 
of the eventual alterations with bidirectional sequencing 
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